Calliditas Therapeutics Ab ((CALT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Calliditas Therapeutics AB is conducting a clinical study titled An Open-label Study to Assess the Efficacy and Safety of Extended TARPEYO® (Delayed-release Budesonide Capsules) Treatment in Adult Patients With Primary IgA Nephropathy Who Have Completed 9 Months of TARPEYO® 16 mg Once Daily Treatment in Real-world Clinical Practice. The study aims to evaluate the long-term benefits of extended TARPEYO® treatment in reducing proteinuria and protecting kidney function in patients with IgA nephropathy.
The intervention involves the use of TARPEYO®, a delayed-release budesonide capsule, initially administered at 16 mg daily for six months, followed by a reduced dose of 8 mg daily for nine months, and a tapering period with 4 mg daily. This treatment targets reducing proteinuria and maintaining kidney health over two years.
The study follows an interventional, open-label design with a sequential intervention model. There is no masking involved, and the primary purpose is treatment-focused.
The study started on December 17, 2024, with an estimated primary completion date yet to be announced. The last update was submitted on June 30, 2025. These dates are crucial for tracking the study’s progress and potential impact on the market.
This clinical update could influence Calliditas Therapeutics’ stock performance by potentially increasing investor confidence if the results show significant treatment benefits. The study’s progress might also affect the competitive landscape in the nephrology treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.